Murphy Pohlad Asset Management’s Edwards Lifesciences EW Stock Holding History

Murphy Pohlad Asset Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,664	Closed	-$255K	–	120
2024 Q1	$255K	Hold	2,664	–	–	0.1%	105
2023 Q4	$203K	Buy	+2,664	New	+$185K	0.08%	109
2023 Q3	–	Sell	-2,664	Closed	-$251K	–	114
2023 Q2	$251K	Hold	2,664	–	–	0.11%	102
2023 Q1	$220K	Buy	+2,664	New	+$209K	0.09%	110
2022 Q4	–	Sell	-2,664	Closed	-$220K	–	117
2022 Q3	$220K	Hold	2,664	–	–	0.1%	108
2022 Q2	$253K	Buy	+2,664	New	+$276K	0.11%	104
2022 Q1	–	Sell	-2,664	Closed	-$345K	–	114
2021 Q4	$345K	Hold	2,664	–	–	0.14%	96
2021 Q3	$301K	Hold	2,664	–	–	0.12%	97
2021 Q2	$275K	Hold	2,664	–	–	0.11%	103
2021 Q1	$222K	Hold	2,664	–	–	0.1%	99
2020 Q4	$243K	Hold	2,664	–	–	0.12%	92
2020 Q3	$212K	Buy	+2,664	New	+$208K	0.11%	96
2020 Q1	–	Sell	-2,664	Closed	-$207K	–	101
2019 Q4	$207K	Buy	+2,664	New	+$208K	0.11%	96

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Murphy Pohlad Asset Management's EW Position: Q2 2024 in Review

Murphy Pohlad Asset Management sold out of Edwards Lifesciences (EW) in Q2 2024, closing a stake of 2,664 shares — an estimated $255K sold.

Murphy Pohlad Asset Management first reported a position in EW in Q4 2019 and held it in 13 quarters. The position peaked at $345K in Q4 2021. 1,296 funds tracked by Wall St. Rank hold EW as of Q2 2024.

Murphy Pohlad Asset Management reported no remaining Edwards Lifesciences position as of Q2 2024 after selling out during the quarter.
Murphy Pohlad Asset Management sold 2,664 Edwards Lifesciences shares in Q2 2024, an estimated $255K.
Murphy Pohlad Asset Management first reported a position in Edwards Lifesciences in Q4 2019 and held it in 13 quarters.
Murphy Pohlad Asset Management's Edwards Lifesciences position peaked at $345K in Q4 2021.
1,296 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2024.

Based on Murphy Pohlad Asset Management's 13F filing for Q2 2024, filed 17 Jul 2024.